Nine-valent HPV vaccine is used to prevent cervical cancer caused by human papillomavirus (HPV) infection, which can prevent more than 90% of cervical cancer. The vaccine was approved for marketing in the United States in 20 14.
On April 28th, 20 18, the State Administration of Pharmaceutical Products conditionally approved the marketing of nine-valent HPV vaccine for preventing cervical cancer in China. Vaccination is primary prevention and screening is secondary prevention, both of which are equally important. Therefore, screening measures for cervical cancer cannot be relaxed because of vaccination.
Inoculated population
The age range of nine-valent HPV vaccine approved for marketing in China is 16-26-year-old women. The reason for this age group is from three aspects:
1. Clinical trials supporting the marketing of this vaccine include1women aged 6-26. At this age, the data of overseas clinical research and the protective effect of vaccines on persistent infection in East Asian people show that the advantages outweigh the disadvantages.
2. The probability of having sex with girls aged 9 ~ 15 in China is very low. Vaccinators aged 9 ~ 15 only carried out immune bridging test, and the clinical research data of East Asian Chinese population in this test were limited.
3. Women over the age of 26 may have a history of virus exposure and infection, but there is no evidence to prove that this vaccine has a protective effect on exposed people of this age.
The above contents refer to:
Baidu encyclopedia-nine-valent HPV vaccine